Primary amyloidosis pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 20: Line 20:
* Primary amyloidosis is characterized by multi-organ deposition of immunoglobulin light chains of lambda variety. These light chains are normal components of antibodies produced by plasma cells (fully differentiated B cells). The [[Plasma cell|plasma cells]] are involved in [[antibody]] production under physiological conditions via reorganization of [[immunoglobulin]] [[Heavy chains|heavy]] and [[Light chain|light chains]].
* Primary amyloidosis is characterized by multi-organ deposition of immunoglobulin light chains of lambda variety. These light chains are normal components of antibodies produced by plasma cells (fully differentiated B cells). The [[Plasma cell|plasma cells]] are involved in [[antibody]] production under physiological conditions via reorganization of [[immunoglobulin]] [[Heavy chains|heavy]] and [[Light chain|light chains]].
* Since primary amyloidosis occurs in patients suffering from plasma cell dyscrasias, the inciting event for primary or AL amyloidosis is formation of an unstable misfolded secondary or tertiary structure of a monoclonal plasma cell-derived immunoglobulin light chain.
* Since primary amyloidosis occurs in patients suffering from plasma cell dyscrasias, the inciting event for primary or AL amyloidosis is formation of an unstable misfolded secondary or tertiary structure of a monoclonal plasma cell-derived immunoglobulin light chain.
'''Role of plasma cells in primary (AL) amyloidosis'''
* In primary amyloidosis, the marrow plasma cell burden is < 10% therefore, primary amyloidosis is not considered a neoplasm. Due to monoclonal proliferation of these mature B cells, only one type of a unique protein sequence is synthesized.
* Studies have shown that in immunoglobulins produced by monoclonal plasma cell proliferation, there is alteration in the dimer interface formed between the variable domain of the light chains and the variable domain of the heavy chains. Mutations that disrupt immunoglobulin folds (structural domain) of beta strands lead to abnormal folding and decreased thermodynamic stability.
* Therefore, destabilizing somatic mutations are present in both the complementarity-determining regions and structural regions of light chains and are thought to increase the propensity to develop insoluble aggregates.
* Because of somatic hypermutations, the amino acid sequence of the pathogenic AL protein differs in each patient
'''Interaction of amyloid fibrils with microenvironment'''
* Accumulation of insoluble amyloid fibrils in tissues leads to activation proteosomes that lead to their endoproteolysis and release of amyloidogenic light chain fragments.
* Interaction of these deposits with extracellular chaperones, matrix components including glycosaminoglycans (GAGs) and collagen, shear forces, endoproteases, and metals modulate aggregation and oligomer formation.
'''Tissue damage'''

Revision as of 23:34, 29 October 2019

Primary amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Primary amyloidosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Primary amyloidosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Primary amyloidosis pathophysiology

CDC on Primary amyloidosis pathophysiology

Primary amyloidosis pathophysiology in the news

Blogs on Primary amyloidosis pathophysiology

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Primary amyloidosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]Sabawoon Mirwais, M.B.B.S, M.D.[3]

Overview

Amyloid is an abnormal insoluble extracellular protein that deposits in the different tissues and causes organic dysfunction and a wide variety of clinical syndromes. In primary amyloidosis, amyloid gradually accumulate and amyloid deposition is widespread in the viscera (mainly kidneys, heart and liver), blood vessel walls, and in the different connective tissues. Primary (AL) amyloidosis) is the most common type of amyloidosis. It results from aggregation and deposition of monoclonal immunoglobulin (Ig) light chains that usually produced by plasma cell clones.

Pathophysiology

Amyloid is an abnormal insoluble extracellular protein that deposits in the different tissues and causes organic dysfunction and a wide variety of clinical syndromes. In primary amyloidosis, amyloid gradually accumulate and amyloid deposition is widespread in the viscera (mainly kidneys, heart and liver), blood vessel walls, and in the different connective tissues.

Pathogenesis

Amyloids

  • Amyloids consist of aggregated proteins that accumulate extracellularly as insoluble fibrils of misfolded proteins. Pathogenic amyloids are the consequence of previously normal proteins that lose their physiological properties and assume a beta-pleated quaternary configuration with a characteristic appearance on electron microscopy. The axis of the fiber (5-15nm in width) in these deposits is perpendicular to antiparallel chains of beta peptides.
  • These misfolded proteins are seen in various diseases such as Alzheimer's disease (beta-amyloid), diabetes mellitus type 2 (amylin), Parkinson's disease (alpha-synuclein), fatal familial insomnia (PrPsc), Huntington's disease (Huntingtin), medullary carcinoma of the thyroid (calcitonin), atherosclerosis (apolipiprotein A-I), rheumatoid arthritis (serm amyloid A), Lattice corneal dystrophy (keratoepithelin) and trasnmissible spongiform encephalopathy (PrP).

Light chain amyloid or AL amyloid

  • Primary amyloidosis is characterized by multi-organ deposition of immunoglobulin light chains of lambda variety. These light chains are normal components of antibodies produced by plasma cells (fully differentiated B cells). The plasma cells are involved in antibody production under physiological conditions via reorganization of immunoglobulin heavy and light chains.
  • Since primary amyloidosis occurs in patients suffering from plasma cell dyscrasias, the inciting event for primary or AL amyloidosis is formation of an unstable misfolded secondary or tertiary structure of a monoclonal plasma cell-derived immunoglobulin light chain.

Role of plasma cells in primary (AL) amyloidosis

  • In primary amyloidosis, the marrow plasma cell burden is < 10% therefore, primary amyloidosis is not considered a neoplasm. Due to monoclonal proliferation of these mature B cells, only one type of a unique protein sequence is synthesized.
  • Studies have shown that in immunoglobulins produced by monoclonal plasma cell proliferation, there is alteration in the dimer interface formed between the variable domain of the light chains and the variable domain of the heavy chains. Mutations that disrupt immunoglobulin folds (structural domain) of beta strands lead to abnormal folding and decreased thermodynamic stability.
  • Therefore, destabilizing somatic mutations are present in both the complementarity-determining regions and structural regions of light chains and are thought to increase the propensity to develop insoluble aggregates.
  • Because of somatic hypermutations, the amino acid sequence of the pathogenic AL protein differs in each patient

Interaction of amyloid fibrils with microenvironment

  • Accumulation of insoluble amyloid fibrils in tissues leads to activation proteosomes that lead to their endoproteolysis and release of amyloidogenic light chain fragments.
  • Interaction of these deposits with extracellular chaperones, matrix components including glycosaminoglycans (GAGs) and collagen, shear forces, endoproteases, and metals modulate aggregation and oligomer formation.

Tissue damage